Cencora Inc.

Cencora Inc. Earnings Recaps

COR Healthcare 3 recaps
Q2 2026 May 9, 2026

Cencora’s shares plunged 16.4% following the quarter as investors reacted negatively to the cautious outlook and signs of underlying deceleration despite management’s positive framing of growth and margin initiatives.

Key takeaways
  • Adjusted diluted EPS rose 7.5% to $4.75, reflecting operational gains but insufficient to reassure the market.
  • Consolidated revenue increased 4% to $78.4 billion, driven by growth across segments but with indications of slowing momentum.
  • Operating income grew in the U.S. and International Healthcare Solutions segments, yet margin pressures and incremental costs from portfolio optimization weighed on profitability.
  • Management highlighted specialty pharmaceuticals expansion and digital investments, but these failed to offset concerns about segment performance and guidance.
  • The company resumed opportunistic share repurchases, signaling confidence, but the broader market reaction suggests skepticism about sustainability and outlook.
Full recap
Q1 2026 Feb 4, 2026

Cencora, Inc. reported a strong start to fiscal 2026, achieving adjusted operating income growth of 12% and adjusted diluted EPS growth of 9% driven by strategic investments and acquisitions.

Key takeaways
  • Completed acquisition of OneOncology, enhancing capabilities and strengthening market position in specialty pharmaceuticals.
  • Raised fiscal 2026 guidance, projecting adjusted operating income growth of 11.5% to 13.5%.
  • Continued strength in U.S. healthcare solutions business, driven by a pharmaceutical-centric strategy and advanced analytics.
  • Significant advancements in clinical research and patient care through MSO expansion, positioning Cencora as a leader in the healthcare ecosystem.
  • Ongoing focus on enhancing patient access to innovative specialty medications and treatments through supportive operational frameworks.
Full recap
Q4 2025 Nov 6, 2025

Cencora reported robust fiscal 2025 results, with adjusted operating income and diluted EPS growth of 16%, driven by strategic investments in specialty services and strong pharmaceutical utilization trends. The company has raised its long-term guidance for adjusted operating income and EPS growth amid a positive market outlook.

Key takeaways
  • Adjusted operating income and diluted EPS rose by 16%, reflecting effective strategic positioning in the specialty market.
  • Cencora is prioritizing growth-oriented investments, including a $1 billion commitment to enhance its distribution network through 2030.
  • The company is strategically reviewing non-core businesses, such as the Animal Health segment, to streamline focus and enhance operational alignment.
  • Long-term guidance has been updated to reflect expected adjusted operating income growth of 6% to 9% and adjusted EPS growth of 9% to 13%.
Full recap